Calidi Biotherapeutics Adds Ex-Genentech and Celgene Veteran Dr. Corsee Sanders to Board
CLDI•Calidi Biotherapeutics appointed Corsee Sanders, Ph.D., as an independent director effective June 17, 2026, leveraging her 30+ years of global clinical operations leadership at Genentech/Roche, Celgene and BMS. Sanders will guide advancement of Calidi’s CLD-401 candidate and RedTail platform into IND-enabling studies and early clinical trials.
1. Appointment Details
Effective June 17, 2026, Calidi Biotherapeutics named Corsee Sanders, Ph.D., as an independent member of its Board of Directors to support corporate governance and strategic oversight.
2. Expertise and Background
Sanders brings over 30 years of biopharmaceutical experience, including senior leadership roles at Genentech/Roche in global clinical operations and industry collaboration, and as an Executive Vice President at Celgene following the Juno acquisition, plus advisory work at BMS.
3. Implications for Pipeline
Her deep expertise in clinical development is expected to strengthen Calidi’s efforts to advance its leading oncolytic virus candidate CLD-401 and expand the RedTail platform through IND-enabling studies and initial human trials.
